The Efficacy of Fermented Milk Drink With Lacticaseibacillus Paracasei Strain Shirota (LcS) on Relieving Constipation-Related Symptoms of Filipino Adults

The primary purpose of this study is to investigate whether the consumption of a probiotic drink (with Lacticaseibacillus paracasei strain Shirota (LcS)) relieves constipation-related symptoms of Filipino adults, specifically its effect on stool consistency, frequency, and duration, and on gastrointestinal discomfort.

开始日期2025-08-18

申办/合作机构

University of Santo Tomas

[+1]

JPRN-UMIN000047263

/ CompletedN/AIIT

Analysis of gene expression profiles of Lacticaseibacillus paracasei strain Shirota from human faeces after drinking products containing LcS. - Analysis of gene expression profiles of Lacticaseibacillus paracasei strain Shirota from human faeces after drinking products containing LcS.

开始日期2022-04-16

申办/合作机构-

ISRCTN87042793

/ CompletedN/A

Evaluation of the impact of fermented milk containing Lactobacillus casei strain Shirota (LcS) on stool consistency in healthy subjects producing hard stools

开始日期2021-08-09

申办/合作机构

Yakult Honsha Co., Ltd.

100 项与 LCS干混悬剂相关的临床结果

登录后查看更多信息

100 项与 LCS干混悬剂相关的转化医学

登录后查看更多信息

100 项与 LCS干混悬剂相关的专利（医药）

登录后查看更多信息

274

项与 LCS干混悬剂相关的文献（医药）

2025-08-11·BMC CANCER

Lung cancer screening experiences among patients with a smoking history and primary care providers: a qualitative study.

Article

作者: Cameron, Sarah ; Sacasa, Nathalia Gutierrez ; Tambou, Olive ; Berman, Gabriel ; Balletto, Brittany ; Rosen, Rochelle ; Busch, Andrew M ; Carey, Michael P ; Walaska, Kristen ; Clark, Melissa A ; Japuntich, Sandra J

BACKGROUND:

Lung cancer screening (LCS) with low dose CT can identify early-stage lung cancer and reduce lung cancer mortality. LCS is underutilized. Patient and provider concerns and experiences may contribute to low utilization.

OBJECTIVE:

To categorize patient and provider experiences with lung cancer screening to identify barriers to utilization.

DESIGN:

Mixed methods study with a survey plus a qualitative interview.

PARTICIPANTS:

Participants were 50 patients aged 55-80 with a smoking history and 7 primary care physicians in the United States.

METHODS:

Participants were interviewed about LCS perceptions and experiences. Transcripts were double-coded and an Applied Thematic Analysis identified key themes.

RESULTS:

Thirty-two patients (68% of those with valid data) met US Preventive Services Taskforce guideline criteria for lung cancer screening, 11 (22%) self-reported tests consistent with LCS. Five main themes emerged: (1) Patient knowledge about LCS is low, even among those screened. Provider knowledge is high. (2) Low dose CT for LCS is well tolerated by patients and acceptable to providers. (3) Provider behavior is influenced by public health guidelines but not insurance coverage. (4) Shared decision-making is not always engaged in. (5) System barriers in the referral process affect LCS receipt despite patient interest in LCS.

CONCLUSIONS:

LCS is well tolerated by patients and valued by providers. To increase LCS knowledge and uptake, systems changes are needed to facilitate shared decision-making conversations, simplify the referral process, and provide care navigation to increase patient logistical barriers to uptake.

2025-07-01·LUNG CANCER

Geographic disparities in lung cancer screening uptake in the United States using the 2021 United States Preventive Services Task Force Guidelines

Article

作者: Hirko, Kelly A ; Das, Abhery ; Peterson, Caryn E ; Fitzgibbon, Marian L ; Byrne, Cecily ; Gudina, Abdi T

INTRODUCTION:

While previous studies documented variability in lung cancer screening (LCS) based on demographic, socioeconomic, and health related factors, less is known about geographic variation in LCS uptake. Using a nationally representative sample, we examined LCS uptake under the revised 2021 United States Preventive Services Taskforce guidelines according to U.S. Census region and metropolitan status.

METHODS:

Data were obtained from the 2022 Behavioral Risk Factor Surveillance System. Multivariable logistic regression models were used to examine associations between geographic region and LCS uptake. Stratified analysis was conducted to assess variability in LCS uptake by metropolitan status within each region.

RESULTS:

Overall, 17.24% of eligible participants underwent LCS in 2022. LCS uptake was highest in the Northeast (21.95%) followed by the Midwest (17.74%) and the South (16.68%), while the lowest LCS uptake was reported in the West (13.41%). Individuals residing in the South (OR: 0.73; 95% CI: 0.66-0.81), Midwest (OR: 0.78; 95% CI: 0.71-0.86), and West (OR: 0.56; 95% CI: 0.51-0.63) were less likely to undergo LCS than those in the Northeast. LCS uptake was 18% lower among those residing in rural than their urban counterparts (OR: 0.82; 95% CI: 0.76-0.88). In stratified analysis, LCS uptake was significantly lower in rural areas than urban areas within each U.S. census region.

CONCLUSION:

Findings suggest considerable variability in LCS across U.S. geographic regions, with lower uptake in areas with higher lung cancer burden. To reduce lung cancer disparities, geographically targeted interventions to promote LCS may be warranted.

2025-07-01·JOURNAL OF NUTRITION

Impact of Probiotic Lacticaseibacillus paracasei Strain Shirota (LcS) on Aflatoxin Exposure among Healthy Malaysian Adults: A Randomized, Double-Blind, Placebo-Controlled Intervention Study

Article

作者: Sabran, Mohd Redzwan ; Yong, Heng Yaw ; Wang, Jia-Sheng ; Akiyama, Takuya ; Chang, Wei Lin ; Abu Saad, Hazizi ; Hassan, Faezah ; Jamaluddin, Rosita

BACKGROUND:

Limited evidence suggests that probiotic Lacticaseibacillus paracasei strain Shirota (LcS) may reduce aflatoxin exposure in Malaysians, though individual factors influencing aflatoxin exposure remain unclear.

OBJECTIVES:

This study evaluated the effect of LcS on aflatoxin biomarker concentrations over a 12-wk intervention among healthy Malaysian adults. A secondary objective was to explore the individual factors associated with aflatoxin exposure using baseline data.

METHODS:

A randomized, double-blind, placebo-controlled intervention involved healthy Malaysian adults (aged 20-60) of Chinese, Malay, or Indian ethnicities with elevated urinary aflatoxin M₁ (AFM₁) and serum aflatoxin B₁ (AFB₁)-albumin concentrations. Hundred and seventy-four (n = 174) subjects were randomly and equally assigned (n = 87/group) to consume either fermented milk with LcS (probiotic) (3 × 10¹⁰ CFU/80 mL/bottle) or milk without LcS (placebo) twice/d for 12 wk, with a 4-wk follow-up. Baseline data included sociodemographic characteristics, knowledge, attitude, and practice related to aflatoxin contamination, dietary intake, body weight, and physical activity status. Urine and fasting blood samples were collected every 2 and 4 wk for AFM₁ and AFB₁-lysine adduct analyses, respectively.

RESULTS:

Eighty-five (n = 85) and 82 (n = 82) subjects in the probiotic and placebo groups completed the intervention, respectively. After adjusting for covariates, a significant effect was observed at postintervention in the probiotic group with a 23% reduction in urinary AFM₁ concentrations compared with the placebo group (B = -0.26; Exp(B) = 0.77; P = 0.04). Serum AFB₁-lysine adduct concentrations remained lower in the probiotic group throughout the study. Both aflatoxin biomarkers significantly differed by ethnicity (AFM₁: P = 0.001; AFB₁: P = 0.01). Subjects with lower aflatoxin knowledge had significantly higher AFB₁-lysine concentrations (mean rank = 95.99) than those with higher knowledge (mean rank = 73.57) (P = 0.04). Urinary AFM₁ concentrations were higher with cereal intake (ρ = 0.17, P = 0.03) but lower with protein intake (ρ = -0.18, P = 0.02).

CONCLUSIONS:

Ethnicity, knowledge level, and dietary intake influenced aflatoxin exposure. The benefits of consuming LcS to reduce aflatoxin exposure deserve further attention.

TRIAL REGISTRATION NUMBER:

This trial is registered in the National Medical Research Register (NMRR-16-2693-3230) and clinicaltrials.gov (NCT03882294).

项与 LCS干混悬剂相关的新闻（医药）

2025-05-27

·美通社

养乐多分享益生菌与健康长年科研探索之路

上海 2025年5月27日 /美通社/ -- 2025年5月23日-25日，中国乳制品工业协会第三十一次年会暨2025年中国乳业技术博览会在南京举行。本届盛会吸引了众多国内外专家学者、企业代表及行业意见领袖齐聚一堂，围绕"创新引领消费促进全民营养健康"这一主题，共商乳业高质量发展大计。年会同期还举办了"乳业科学家论坛"，该论坛由国家乳业技术创新中心、中国农业大学营养与健康研究院协办，由中国农业大学任发政教授主持。邀请了来自国家风险评估中心、养乐多本社、浙江大学、中国农业大学、国家乳业技术创新中心的专家分别从完善标准法规、益生菌领域的前沿进展、乳品制造数智化、酶制剂、乳品关键技术与产业创新融合等方面进行了介绍。养乐多本社的长南治董事通过发表《副干酪乳酪杆菌代田株研究的创新成果》主题演讲，与行业分享了养乐多的创新之道。养乐多本社的长南治董事发表主题演讲科研循证 LcS的价值随着生活水平和公众健康意识的提升，活性乳酸菌的健康益处如今被广泛接受。但在二十世纪初，很少有人可以理解为了健康而摄入"活菌"的这一概念。为了让更多人拥有健康美好的生活，养乐多创始人代田稔医学博士开始潜心钻研对肠道有益的乳酸菌。经不懈努力，他终于成功分离并强化培养出对肠道有益的乳酸菌。这种乳酸菌后来以代田稔博士的名字命名为——副干酪乳酪杆菌代田株（ Lacticaseibacillus paracasei strain Shirota，LcS）。副干酪乳酪杆菌代田株（LcS）养乐多本社长南治董事在演讲中回顾了养乐多90多年的科研创新历程。他表示，养乐多始终秉承代田稔博士"预防医学"理念，在益生菌研究领域实现了三次重大跨越。1995年发表在《欧洲泌尿外科》学术期刊上的研究 [1] 首次发现，LcS菌株能将浅表性膀胱癌复发率显著降低至20.8%，这一突破性发现开创了益生菌在疾病干预领域的新纪元。近年来，公司研发的YIF-SCAN ® 肠道菌群检测系统突破了传统方法的局限，为深入研究菌群与健康关系提供了关键技术支撑。通过对LcS菌株的深入研究，科研团队成功解析了其胆汁酸耐受关键基因和细胞壁多糖功能机制，为产业化应用奠定了坚实基础。养乐多独自研发的“YIF-SCAN”肠内菌群解析技术 "我们始终牢记代田博士的初心，"长南董事在发言中强调，"未来将继续深化菌群研究，开发新一代健康解决方案，推动全球预防医学标准体系建设。"从最初的肠道调节到如今的脑肠轴研究，养乐多持续引领着益生菌科研的创新方向。探索不断创新不断养乐多历经九十余载科研探索，始终以科技创新驱动企业发展，其多项突破性研究成果持续引领行业发展。为深入解析活性乳酸菌的作用机制，养乐多构建了全球化科研网络，包括养乐多本社中央研究所和欧洲研究所两大核心研发基地。在中国地区，养乐多重视并积极推进本土化科研合作，与医疗机构及高校建立战略合作关系，重点开展活性乳酸菌在不同人群中的健康效应研究，以科学实证推动产品创新。秉承"不断探索生命科学，为世界人类的健康和美好生活作贡献"的理念，养乐多将LcS的科研成果应用于产品中。面向未来，养乐多将继续在益生菌研究领域投入，与各方合作伙伴解开更多关于肠道菌群与健康之间的奥秘，为全球预防医学事业的发展贡献智慧与力量。 [1] Aso et al, Eur Urol 1995;27(2):104-9.

微生物疗法

2024-11-12

·drugs

Few High-Risk Individuals Have Heard of, Discuss Lung Cancer Screening

TUESDAY, Nov. 12, 2024 -- Few high-risk individuals have heard of or have discussed lung cancer screening (LCS) with a health care practitioner, according to a research letter published online Oct. 30 in JAMA Network Open . Kalyani Sonawane, Ph.D., from the Medical University of South Carolina in Charleston, and colleagues examined LCS communication for U.S. individuals at high risk. Data were included for participants aged 50 to 80 years from the 2022 Health Information National Trends Survey-6, a nationally representative survey of the civilian noninstitutionalized population. A total of 929 participants who formerly smoked and 350 who currently smoke were identified (estimated population sizes, 29.0 and 11.9 million, respectively). The researchers found that 18.1 and 75.1 percent of those who formerly smoked had never heard of LCS and never discussed LCS with their clinician, respectively. In the current smoking group, 13.5 and 71.1 percent, respectively, had never heard of LCS and never discussed LCS with their clinician. In both groups, more than 80 percent of participants had never heard of nor discussed LCS with a clinician, regardless of sex, race, ethnicity, educational attainment, household income, urbanicity versus rurality, health insurance status, and unmet social determinants. Among those with a history of cancer or a comorbid lung disease, more than 60 percent did not discuss LCS with their clinicians. "Our data emphasize the need for increasing LCS communication in the United States, specifically, increasing education and outreach to eligible individuals who can benefit from LCS," the authors write. Several authors disclosed ties to industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

2023-11-09

·美通社

中国专家携干酪乳杆菌代田株的最新研究成果亮相国际研讨会

上海 2023年11月9日 /美通社/ -- 10月27日，由养乐多生命科学基金会主办，日本文部科学省支持的第31届肠内菌群国际研讨会在日本成功举行，来自中国、日本、巴西、荷兰等多个国家的约400名专家学者及相关行业人员齐聚一堂，分享、探讨了国际肠内微生态领域的最新研究成果。同期还举办了围绕干酪乳杆菌代田株（ Lactobacillus casei strain Shirota，LcS）菌株探索的研讨会，来自上海交通大学医学院附属瑞金医院神经内科的杨晓东医学博士在研讨会上发表了题为"针对帕金森病患者便秘症状的有效性试验"的演讲，受到与会专家的积极提问和一致好评。第31届肠内菌群国际研讨会流行病语境下的肠道微生物群研究在过去三年里，全球性传染病的流行影响了社会生活的方方面面，也激励着全球各地的专业人士以此为切入点，从多角度探索疾病的防治。本届肠内菌群国际研讨会围绕"肠内菌群与传染性疾病控制"这一主题，邀请了7位来自世界各地的专家发表了精彩演讲。巴西南里奥格兰德天主教大学的Ana Paula Duarte de Souza教授介绍了肠道微生物群及其代谢物在病毒性呼吸道感染中的作用；日本国立国际医疗研究中心的河冈义裕教授发表了关于"应对新型病毒感染的威胁"的演讲；荷兰阿姆斯特丹大学医学中心的Vanessa Harris教授生动形象地介绍了肠道微生物群与轮状病毒疫苗疗效之间的关系：从相关到因果关系。聚焦帕金森人群肠道菌群持续深入探索随着肠道菌群研究的不断深入，近年来，特殊人群的肠胃状况及健康逐渐成为肠道菌群研讨关注的重要课题。上海交通大学医学院附属瑞金医院的杨晓东医学博士团队针对帕金森患者便秘症状开展了研究。帕金森病（Parkinson's disease，PD）是一种神经退行性疾病，随着年龄的增长，患上神经退行性疾病的机会也逐步增加，帕金森作为老年人常见的一种神经退行性疾病，临床表现包括运动症状和一系列非运动症状。运动症状包括震颤、肌强直和动作迟缓，而非运动症状除了便秘等肠道功能障碍，也包括比如认知障碍、自主神经功能障碍和睡眠障碍等。该研究就补充LcS对帕金森病患者临床症状、肠道菌群和粪便代谢物的影响进行了有效性试验。干酪乳杆菌代田株（Lactobacillus casei strain Shirota，LcS）研究共计招募了128位帕金森病患者，年龄在55-80岁之间，随机分为LcS干预组或安慰剂组，分别在每日早餐时服用LcS（100毫升，含1×10 10 个活性LcS的发酵乳）或安慰剂，持续12周。杨晓东医生表示，研究虽然没有发现肠道菌群或粪便代谢物的组成发生显著变化，但LcS干预后显著减轻了患者便秘相关症状及其他非运动症状。证实了LcS在治疗帕金森病患者便秘和其他非运动症状方面具有良好效果。另外，研究还发现与安慰剂组相比，LcS组的酪氨酸浓度在粪便中显著降低，但在血浆中则增加。酪氨酸是多巴胺的前体，而多巴胺是帕金森病患者所缺乏的大脑化学神经递质。这一研究的论文《补充干酪乳杆菌代田株对帕金森病临床症状及肠道菌群的影响》已于今年7月12日在《Food & Function》上正式发表。二十世纪初，养乐多创始人代田稔医学博士发现并强化培养出能够活着到达肠道的活性乳酸菌——LcS。此后，为传承代田理念，养乐多集团不断开展有关LcS的各项研究，在日本与欧洲的两家养乐多研究所内的数百名研究人员，利用各种世界先进技术与设备，对菌群进行着高效率、高精度的分析，更清楚地了解肠内菌群与健康之间的关系，持续探索LcS的健康作用。位于日本东京的养乐多本社中央研究所在中国，养乐多与国内科研单位多次合作开展针对中国人群的LcS研究，在肠内存活性、免疫功能的影响等方向均取得了一定的成果并进行了发表，为展示益生菌的有效性提供了充分的科学论证。同时养乐多还积极支持青年科研人员的探索工作，与中国食品科学技术学会共同设立的肠道健康与益生菌青年科研基金，已通过专家评审确定了3个方向的课题，将为益生菌领域的发展提供更有力的循证基础。未来，养乐多也将不断探索生命科学并加以研究证明，为人类健康发展作出贡献。

微生物疗法临床研究疫苗

100 项与 LCS干混悬剂相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
吻合口溃疡	临床申请批准	中国	厦门恩成制药有限公司	2024-12-16
十二指肠溃疡	临床申请批准	中国	厦门恩成制药有限公司	2024-12-16
反流性食管炎	临床申请批准	中国	厦门恩成制药有限公司	2024-12-16
胃泌素瘤	临床申请批准	中国	厦门恩成制药有限公司	2024-12-16
胃溃疡	临床申请批准	中国	厦门恩成制药有限公司	2024-12-16